Cargando…
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
PURPOSE: Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite the best available treatment, prognosis remains poor. Current standard therapy consists of surgical removal of the tumor followed by radiotherapy and chemotherapy with the alkylating agent temozolomide (T...
Autores principales: | Ehinger, Erik, Kopecky, Jan, Darabi, Anna, Visse, Edward, Edvardsson, Charlotte, Tomasevic, Gregor, Cederberg, David, Belting, Mattias, Bengzon, Johan, Siesjö, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938624/ https://www.ncbi.nlm.nih.gov/pubmed/36803465 http://dx.doi.org/10.1186/s12883-023-03119-4 |
Ejemplares similares
-
Antisecretory Factor May Reduce ICP in Severe TBI—A Case Series
por: Cederberg, David, et al.
Publicado: (2020) -
Intratumoral administration of the antisecretory peptide AF16 cures murine gliomas and modulates macrophage functions
por: Kopecky, Jan, et al.
Publicado: (2022) -
Effect of antisecretory factor, given as a food supplement to adult patients with severe traumatic brain injury (SASAT): protocol for an exploratory randomized double blind placebo-controlled trial
por: Cederberg, David, et al.
Publicado: (2022) -
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas
por: Enríquez Pérez, Julio, et al.
Publicado: (2020) -
Glioblastoma CD105(+) cells define a SOX2(−) cancer stem cell-like subpopulation in the pre-invasive niche
por: Li, Jiaxin, et al.
Publicado: (2022)